Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

doi:10.1016/j.bone.2017.07.019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

Bone - 1 Apr 2018

Kaplan Frederick S, Andolina Jeffrey R, Adamson Peter C, Teachey David T, Finklestein Jerry Z, Ebb David H, Whitehead Benjamin, Jacobs Benjamin, Siegel David M, Keen Richard, Hsiao Edward, Pignolo Robert J

Abstract excerpt

BACKGROUND: Fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disorder of progressive, disabling heterotopic ossification (HO) for which there is presently no definitive treatment. Research studies have identified multiple potential targets for therapy in FOP, and novel drug candidates are being developed for testing in clinical trials. A complementary approach seeks to identify approved drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type I
Share to Bone Morphogenetic Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Imatinib Mesylate

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed

Identifiers

PMID: 28736245
DOI: 10.1016/j.bone.2017.07.019

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.